Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review
Cancer Treatment and Research Communications · 2026 · 47 · 101233
DOI: 10.1016/j.ctarc.2026.101233 ↗Kurz gefasst
Scoping Review in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Victoria L Cammann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Tolvaptan, Inappropriate ADH Syndrome, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland.
- University Medical Library, University of Basel, Basel, Switzerland.
- Department of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland; Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland; Department of Health Sciences and Medicine, Un…
Zitieren
APA
Cammann, V. L., Sheryl, M., Fürst, T., & Jehle, A. W. (2026). Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review. Cancer Treatment and Research Communications, 47, 101233. https://doi.org/10.1016/j.ctarc.2026.101233
Vancouver
Cammann VL, Sheryl M, Fürst T, Jehle AW. Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review. Cancer Treatment and Research Communications. 2026;47:101233. doi:10.1016/j.ctarc.2026.101233
BibTeX
@article{Cammann2026,
author = {Cammann, Victoria L and Sheryl, Menzi and Fürst, Thomas and Jehle, Andreas W},
title = {Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {47},
pages = {101233},
doi = {10.1016/j.ctarc.2026.101233}
}
EUVIMED